RxDoctor Payments Data

Christian Wold, MD

Otolaryngology · Alexandria, LANPI 1801869409

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,651 of the $3,372 with a category attached, or 78.6%. 22 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 49.5% of the total. Reporting peaked in 2019 at $1,373 and has fallen 62.7% since, to $512 in 2025.

$3,372in general payments, 2019–2025

Across 112 payments — averaging $30.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$2K
  • Aerin Medical Inc.$296
  • Optinose US, Inc.$201
  • Sanofi$190
  • Sanofi-aventis U.S. LLC$119
  • GSK$110
  • plus $786 from 16 others

What the payments were for

  • Travel & lodging$62218%
  • Food & beverage$2,65179%
  • Education$993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,372 in reported general payments places this provider in the 75th percentile of 218 otolaryngology providers in Louisiana.

See all otolaryngology providers in Louisiana

Medicare billing

Part B allowed, 2024
$352,624
Medicare patients
1,254
Services billed
3,174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ipratropium Bromide234$5,179
SynthroidLevothyroxine Sodium54$3,629
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth25$3,049
Levothyroxine Sodium434$2,887
Fluticasone Propionate143$1,721
Pantoprazole Sodium196$1,640
Cephalexin63$913
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav86$689
Armour ThyroidThyroid,pork12$499
Doxycycline Hyclate52$369
Mupirocin55$355
Ofloxacin21$317
Clindamycin Hcl25$285
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen71$261
Triamcinolone Acetonide25$250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid, Armour Thyroid$46$4,12966 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 218 otolaryngology providers in Louisiana.

Other otolaryngology in Alexandria

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →